(Q24244045)

3

0 references

author name string

David Roberts

1

0 references

Susan Brunskill

2

0 references

Senani Williams

4

0 references

Jo Howard

5

0 references

Chris Hyde

Cochrane Database of Systematic Reviews

6

0 references

publication date

18 July 2007

0 references

published in

0 references

cites work

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

A multi-center safety trial of the oral iron chelator deferiprone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Deferiprone, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Hepatic lipid peroxidation in vivo in rats with chronic iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Survival and disease complications in thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Deferiprone and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Ocular toxicity of high-dose intravenous desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Results of long-term iron-chelating therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Sensorineural hearing loss in children with thalassemia major in Northern Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Academic freedom in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

21 January 2018

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Prevention of iron loading in transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

The toxic effects of desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Introduction to The Olivieri symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

A Randomized Controlled Study Evaluating the Safety and Efficacy of Deferiprone Treatment in Thalassemia Major Patients from Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

Prolonged survival in patients with beta-thalassemia major treated with deferoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Reassessment of the Use of Desferrioxamine B in Iron Overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Erythropoiesis: Comparison of Cytotoxic Aldehyde Generation in Beta-Thalassemia Patients Chelated with Deferoxamine or Deferiprone (L1) Versus NO Chelation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

High-dose desferrioxamine as a cause of growth failure in thalassemic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Secondary iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB2

7 January 2021